Clovis Oncology submits Investigational New Drug applications to FDA for FAP-2286 for therapeutic and imaging clinical trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced it has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for... Read More

Tuesday December 29, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, FAP-2286, FDA